Ceramide and LPL Biomarkers for Cardiovascular Risk Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cardiovascular (CV) markers such as LDL-C, LDL-P, and total cholesterol are ineffective in identifying patients at risk for cardiovascular events like acute myocardial infarction, acute coronary syndrome, stroke, and CV death, as they fail to predict these events accurately and provide clinically useful predictive information.
Innovation Solution
The use of specific ceramide and lysophospholipid (LPL) markers, including ceramides and LPCs, to predict CV events by determining their concentrations in biological samples and comparing them to control samples, allowing for early identification and treatment of high-risk patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional CV markers (LDL-C, LDL-P, total cholesterol) are used for diagnosis, then the diagnostic process is simple and widely available, but the predictive accuracy for CV events is insufficient
Solution Approach 1:
The patent changes the chemical parameters being measured from traditional cholesterol-based markers to ceramide and lysophospholipid markers. This parameter change enables superior predictive accuracy for CV events by measuring different biochemical pathways that are more directly related to cardiovascular risk, resolving the contradiction between measurement precision and marker complexity.
2Reliability
If ceramide and LPL markers are used for prediction, then the predictive information and sensitivity are improved, but the diagnostic complexity and cost increase
Solution Approach 1:
The patent segments the cardiovascular risk assessment by focusing on specific ceramide and lysophospholipid marker panels rather than measuring all possible lipid markers. This segmentation approach maintains high predictive reliability while reducing test complexity by measuring only the most clinically relevant markers identified through research.
3Loss of information
If comprehensive lipid profiling is performed, then the predictive information for CV events is enhanced, but the ease of operation and clinical usability decreases
Solution Approach 1:
The patent extracts the most critical predictive information from comprehensive lipid profiling by identifying and measuring only specific ceramide and lysophospholipid markers that have been shown to provide the greatest predictive value for CV events. This extraction maintains predictive information quality while improving clinical usability by simplifying the test protocol.
Data Source
AI summary
The present invention inter alia provides a method, and use thereof, of predicting CV events such as AMI, ACS, stroke, and CV death by determining the concentration of at least one ceramide of Formula I or one lysophospholipid of Formula II and/or III and at least one lysophospholipid of Formula IV, V, VI, VII and/or VIII in a biological sample and comparing those concentrations to a control. Finding an increased concentration of the at least one Formula I ceramide or Formula II and/or III lysophospholipid and a decreased concentration of the at least one Formula IV, V, VI, VII and/or VIII lysophospholipid indicates that the subject has an increased risk of developing one or more CV events. The present disclosure also provides a method, and use thereof, of diagnosing subjects suffering acute ischemia. Also provided are kits and compositions comprising the same for use in predicting and/or diagnosing CV events.